Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 74,485 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 74,485 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $67.53, for a total transaction of $5,029,972.05. Following the completion of the sale, the chief executive officer now owns 5,458,502 shares in the company, valued at $368,612,640.06. This represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Tempus AI Stock Up 6.1 %

TEM opened at $68.96 on Friday. The firm has a 50 day moving average of $44.36 and a two-hundred day moving average of $48.84. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TEM. First Horizon Advisors Inc. purchased a new stake in Tempus AI in the third quarter valued at $30,000. Geode Capital Management LLC lifted its holdings in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the period. FNY Investment Advisers LLC acquired a new stake in Tempus AI during the fourth quarter worth about $67,000. IFP Advisors Inc purchased a new position in Tempus AI during the fourth quarter valued at approximately $76,000. Finally, US Bancorp DE acquired a new position in Tempus AI in the fourth quarter valued at approximately $80,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. TD Cowen reaffirmed a “buy” rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a research report on Wednesday. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their price target for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Finally, Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.